Royal Bank of Canada Boosts Stock Holdings in Edwards Lifesciences Corporation $EW

Royal Bank of Canada grew its position in Edwards Lifesciences Corporation (NYSE:EW) by 18.1% during the 1st quarter, HoldingsChannel.com reports. The fund owned 2,446,999 shares of the medical research company’s stock after buying an additional 375,801 shares during the quarter. Royal Bank of Canada’s holdings in Edwards Lifesciences were worth $195,956,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in EW. Hanson & Doremus Investment Management purchased a new stake in shares of Edwards Lifesciences during the first quarter worth approximately $25,000. JPL Wealth Management LLC purchased a new position in Edwards Lifesciences in the 3rd quarter valued at $25,000. MV Capital Management Inc. acquired a new stake in Edwards Lifesciences during the 4th quarter worth $26,000. RMG Wealth Management LLC acquired a new stake in Edwards Lifesciences during the 1st quarter worth $26,000. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth $27,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Up 2.5%

Shares of NYSE EW opened at $85.78 on Thursday. The company has a market capitalization of $49.39 billion, a P/E ratio of 49.30, a P/E/G ratio of 2.10 and a beta of 0.86. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The company has a 50 day simple moving average of $87.83 and a 200-day simple moving average of $83.86. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $96.29.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a return on equity of 15.85% and a net margin of 15.43%.The firm’s quarterly revenue was up 13.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities research analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the sale, the senior vice president directly owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $91.70, for a total transaction of $56,762.30. Following the completion of the sale, the vice president owned 40,034 shares in the company, valued at approximately $3,671,117.80. This trade represents a 1.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 45,577 shares of company stock worth $3,855,527 over the last quarter. 0.31% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on EW. Robert W. Baird increased their target price on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research report on Friday, April 24th. JPMorgan Chase & Co. boosted their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Piper Sandler reiterated an “overweight” rating and issued a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. Finally, Canaccord Genuity Group set a $85.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, April 24th. Seventeen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.